Trial Profile
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms C_ASCENT
- 23 Mar 2020 Results (n=6) of substudy A5335S published in the Journal of Infectious Diseases
- 11 Mar 2020 Results analysing T-Cell and Monocyte Activation Correlate and Decline During Hcv Therapy for Hcv/Hiv, presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 16 May 2019 Status changed from completed to discontinued.